# Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

> **NCT00272181** · PHASE2 · TERMINATED · sponsor: **Sesen Bio, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma, Squamous Cell
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Mouth Neoplasms
- Head and Neck Cancer

## Interventions

- **DRUG:** Proxinium

## Key facts

- **NCT ID:** NCT00272181
- **Lead sponsor:** Sesen Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Slow accrual in North America
- **Last updated:** 2015-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272181, "Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00272181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*